Rodney L Piatt Net Worth

The estimated Net Worth of Rodney L Piatt is at least $691 Thousand dollars as of 22 June 2017. Rodney Piatt owns over 3,653 units of Mylan NV stock worth over $691,266 and over the last 10 years Rodney sold MYL stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Rodney Piatt MYL stock SEC Form 4 insiders trading

Rodney has made over 3 trades of the Mylan NV stock since 2016, according to the Form 4 filled with the SEC. Most recently Rodney exercised 3,653 units of MYL stock worth $57,900 on 22 June 2017.

The largest trade Rodney's ever made was exercising 3,653 units of Mylan NV stock on 22 June 2017 worth over $57,900. On average, Rodney trades about 1,497 units every 60 days since 2015. As of 22 June 2017 Rodney still owns at least 43,613 units of Mylan NV stock.

You can see the complete history of Rodney Piatt stock trades at the bottom of the page.

What's Rodney Piatt's mailing address?

Rodney's mailing address filed with the SEC is ALBANY GATE, DARKES LANE, , POTTERS BAR, HERTFORDSHIRE, X0, EN6 1AG.

Insiders trading at Mylan NV

Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher, and Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.

What does Mylan NV do?

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Complete history of Rodney Piatt stock trades at Mylan NV

Mylan NV executives and stock owners

Mylan NV executives and other stock owners filed with the SEC include:

• Heather Bresch,
  Chief Executive Officer, Executive Director
• Rajiv Malik,
  President, Executive Director
• Robert Coury,
  Executive Chairman of the Board
• Mark Parrish,
  Lead Independent Non-Executive Vice Chairman of the Board
• JoEllen Dillon,
  Non-Executive Independent Director
• Neil Dimick,
  Non-Executive Independent Director
• Melina Higgins,
  Non-Executive Independent Director
• Sjoerd Vollebregt,
  Non-Executive Independent Director
• Robert Cindrich,
  Non-Executive Independent Director
• Harry Korman,
  Non-Executive Independent Director
• Randall Vanderveen,
  Non-Executive Independent Director
• Pauline van der Meer Mohr,
  Non-Executive Independent Director
• Richard Mark,
  Non-Executive Independent Director
• Melissa Trombetta,
  Head of Global Investor Relations
• Joseph C Md Maroon,
  Director
• Rodney L Piatt,
  Director
• Paul Campbell,
  See Remarks
• Laboratories Abbott Product...,
  
• Kenneth Scott Parks,
  Chief Financial Officer
• Wendy Cameron,
  Director
• Douglas J Leech,
  Director
• Daniel Martin Jr Gallagher,
  Chief Legal Officer
• Anthony Mauro,
  Chief Commercial Officer
• John D Sheehan,
  EVP and CFO
• Laboratories Abbott Establi...,
  
• Laboratories Laboratoires F...,